Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Indivior Pharmaceuticals Inc. (INDV)

NASDAQ: INDV · Pharmaceutical Preparations · Rockville, MD

Our rating: Cautious

Cautious reaffirmed at $35.37, moderate conviction, October 30, 2026.

Breaks if: The Cautious call would be wrong if free cash flow turns positive on a trailing-twelve-month basis in two consecutive quarterly reports by mid-2027 and the gap between net income and FCF narrows below $50M — signaling the cash drag has resolved and earnings quality has improved. From a price standpoint, a move above $42.44 (roughly 20% from the current $35.37) within six months, in the absence of any deterioration in the underlying reported figures, would also challenge the view.

Key figures

Market value$4.3B
Revenue, last 12 months$1.4B
Net income, last 12 months$450M
Free cash flow, last 12 months$31M
Price to earnings9.5×
Free cash flow yield0.7%
Dividend yield0.0%
Operating margin40.6%
Return on equityn/a
Beta to the S&P 5000.65
Volatility, annualized52.8%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$356M13.4%$1.12$83M
June 30, 2026$343M13.6%$0.98$222M
March 31, 2026$317M19.2%$0.69−$29M
December 31, 2025$358M19.7%$0.79−$245M
September 30, 2025$314M2.3%$0.33−$59M
June 30, 2025$302M1.0%$0.14$141M
March 31, 2025$266M−6.3%$0.38$70M
December 31, 2024$299Mn/a$0.16−$33M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

13 ledger entries and 18 corporate events on record. Share price as of November 2, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.